Physician profile
Manoj Mathew
NPI 1467572107
$17,735.87
in general payments reported to CMS, 2019-2025
33 companies · $4,378 in 2025
The $4,378 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,243 · 2020: $3,177 · 2021: $247 · 2022: $22.92 · 2023: $1,649 · 2024: $19.26 · 2025: $4,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $1,911 · Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $1,910.82 |
| Food and Beverage | $135.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,001.94 | 2019-2021 | |
| Intuitive Surgical, INC. | $4,378.16 | 2025 | |
| Medical Device Business Services, INC. | $1,586.85 | 2023 | Monarch |
| Stryker Corporation | $500.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.42 | 2019-2021 | |
| Glaxosmithkline, LLC. | $264.67 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $204.66 | 2019-2021 | |
| Philips North America LLC | $168.49 | 2019-2020 | |
| Mylan Specialty L.P. | $136.14 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $123.60 | 2019-2021 | |
| Genentech USA, INC. | $112.20 | 2019 | |
| Insmed, INC. | $90.48 | 2019-2020 | |
| Advanced Respiratory, INC | $81.02 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $59.44 | 2020 | |
| Shire North American Group INC | $57.46 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.83 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $52.39 | 2019-2020 | |
| Abbvie INC. | $51.68 | 2022-2023 | |
| United Therapeutics Corporation | $50.87 | 2019-2020 | |
| Genzyme Corporation | $48.78 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.28 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $39.49 | 2020 | |
| Electromed, INC. | $35.77 | 2019 | |
| Harmony Biosciences LLC | $35.24 | 2020-2021 | |
| Circassia INC. | $33.86 | 2019-2020 | |
| Ethicon INC. | $32.94 | 2023 | Monarch Platform |
| Getinge USA Sales, LLC | $32.75 | 2021 | |
| Zoll Respicardia, INC. | $19.26 | 2024 | Remede System |
| Veran Medical Technologies, INC. | $15.32 | 2020 | |
| Pulmonx Corporation | $13.35 | 2020 | |
| Vapotherm INC | $13.16 | 2019 | |
| Allergan, INC. | $13.09 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.